Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Biomarin’s next chapter; Amgen’s obesity plans; Daiichi’s new ADC data; Acelyrin hit by clinical failure; and Skyrizi beats Stelara in Crohn’s.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 15 September 2023, including: BioMarin Pharmaceutical Inc.’s next chapter; Amgen, Inc.’s obesity plans; Daiichi Sankyo Co., Ltd.’s new ADC data; Acelyrin, Inc. hit by clinical failure; and Skyrizi beats Stelara in Crohn’s.
This and all our other podcasts are available on the Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "BioMarin’s Next Chapter: ‘A Financial Growth Story’" - Scrip, 13 Sep, 2023.)
(Also see "Amgen’s Plan To Go Big In Obesity" - Scrip, 12 Sep, 2023.)
(Also see "Daiichi Sankyo Comes Out Swinging At WCLC As ADCs Steal Show" - Scrip, 11 Sep, 2023.)
(Also see "Acelyrin Goes From Float To Sink" - Scrip, 12 Sep, 2023.)
(Also see "AbbVie’s Skyrizi Bests Stelara Head-To-Head In Crohn’s" - Scrip, 12 Sep, 2023.)